Published in Cancer Cell on November 01, 2007
Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet (2012) 15.21
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
A high-resolution, nucleosome position map of C. elegans reveals a lack of universal sequence-dictated positioning. Genome Res (2008) 7.77
Epigenetics in cancer. Carcinogenesis (2009) 7.49
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
Rethinking how DNA methylation patterns are maintained. Nat Rev Genet (2009) 4.03
Chromatin structure and the inheritance of epigenetic information. Nat Rev Genet (2010) 4.03
Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell (2010) 2.80
Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. Mol Cell Biol (2009) 2.34
Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res (2009) 2.31
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet (2010) 2.27
Polycomb-repressed genes have permissive enhancers that initiate reprogramming. Cell (2011) 2.14
Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res (2012) 1.95
Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer (2010) 1.93
H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes. Mol Cell (2010) 1.85
DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet (2011) 1.83
CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene (2010) 1.65
Reconfiguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer. Genome Res (2014) 1.63
Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci (2010) 1.61
Active VSG expression sites in Trypanosoma brucei are depleted of nucleosomes. Eukaryot Cell (2009) 1.51
Multiple sequence-specific factors generate the nucleosome-depleted region on CLN2 promoter. Mol Cell (2011) 1.49
Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol Cell Biol (2008) 1.36
Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol Cell Biol (2011) 1.34
The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res (2009) 1.32
Chromatin, cancer and drug therapies. Mutat Res (2008) 1.21
Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res (2010) 1.20
Modulation of histone methylation and MLH1 gene silencing by hexavalent chromium. Toxicol Appl Pharmacol (2009) 1.12
Effects of DNA methylation on the structure of nucleosomes. J Am Chem Soc (2011) 1.09
Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res (2013) 1.09
Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions. PLoS Genet (2012) 1.07
Analysis of individual remodeled nucleosomes reveals decreased histone-DNA contacts created by hSWI/SNF. Nucleic Acids Res (2009) 1.07
The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. Oncogene (2013) 1.05
Long-term stability of demethylation after transient exposure to 5-aza-2'-deoxycytidine correlates with sustained RNA polymerase II occupancy. Mol Cancer Res (2010) 1.04
De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. Int J Cancer (2011) 1.02
Targeting the cancer epigenome for therapy. Nat Rev Genet (2016) 1.01
Histone modifications and chromatin organization in prostate cancer. Epigenomics (2010) 0.99
Mitochondrial regulation of epigenetics and its role in human diseases. Epigenetics (2012) 0.98
DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11. Epigenetics (2013) 0.96
Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer (2014) 0.95
MethylViewer: computational analysis and editing for bisulfite sequencing and methyltransferase accessibility protocol for individual templates (MAPit) projects. Nucleic Acids Res (2010) 0.95
Lsh mediated RNA polymerase II stalling at HoxC6 and HoxC8 involves DNA methylation. PLoS One (2010) 0.95
The role of DNA methylation in directing the functional organization of the cancer epigenome. Genome Res (2015) 0.94
Single-molecule analysis of chromatin: changing the view of genomes one molecule at a time. J Cell Biochem (2008) 0.91
Helicobacter pylori CagA: From Pathogenic Mechanisms to Its Use as an Anti-Cancer Vaccine. Front Immunol (2013) 0.91
Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers. Int J Cancer (2011) 0.90
The epigenetics of renal cell tumors: from biology to biomarkers. Front Genet (2012) 0.89
Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy. Clin Epigenetics (2015) 0.88
Genomic and Epigenomic Alterations in Cancer. Am J Pathol (2016) 0.86
Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure. PLoS Genet (2013) 0.86
Epigenetic field defects in progression to cancer. World J Gastrointest Oncol (2013) 0.86
DNA methylation determines nucleosome occupancy in the 5'-CpG islands of tumor suppressor genes. Oncogene (2013) 0.86
Nucleosomes correlate with in vivo progression pattern of de novo methylation of p16 CpG islands in human gastric carcinogenesis. PLoS One (2012) 0.86
Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis. Ann Surg Oncol (2009) 0.85
Treatment of breast cancer cells with DNA demethylating agents leads to a release of Pol II stalling at genes with DNA-hypermethylated regions upstream of TSS. Nucleic Acids Res (2011) 0.84
CpG islands undermethylation in human genomic regions under selective pressure. PLoS One (2011) 0.83
Identification and characterization of putative methylation targets in the MAOA locus using bioinformatic approaches. Epigenetics (2010) 0.83
c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells. BMC Cancer (2011) 0.83
Nucleosomes at active promoters: unforgettable loss. Cancer Cell (2007) 0.82
Epigenetic inactivation of FAT4 contributes to gastric field cancerization. Gastric Cancer (2016) 0.82
Breaching the boundaries that safeguard against repression. Mol Cell (2009) 0.81
Vitamin and antioxidant rich diet increases MLH1 promoter DNA methylation in DMT2 subjects. Clin Epigenetics (2012) 0.79
Altered promoter nucleosome positioning is an early event in gene silencing. Epigenetics (2014) 0.79
3-D DNA methylation phenotypes correlate with cytotoxicity levels in prostate and liver cancer cell models. BMC Pharmacol Toxicol (2013) 0.79
DNA methyltransferase accessibility protocol for individual templates by deep sequencing. Methods Enzymol (2012) 0.79
Local depletion of DNA methylation identifies a repressive p53 regulatory region in the NEK2 promoter. J Biol Chem (2013) 0.78
The influence of DNA sequence on epigenome-induced pathologies. Epigenetics Chromatin (2012) 0.77
Factors affecting the persistence of drug-induced reprogramming of the cancer methylome. Epigenetics (2016) 0.77
Genome-wide profiling of DNA methylation and gene expression in esophageal squamous cell carcinoma. Oncotarget (2016) 0.77
Early-Stage Induction of SWI/SNF Mutations during Esophageal Squamous Cell Carcinogenesis. PLoS One (2016) 0.76
Stereochemical control of nucleosome targeting by platinum-intercalator antitumor agents. Nucleic Acids Res (2015) 0.76
Dissecting epigenetic silencing complexity in the mouse lung cancer suppressor gene Cadm1. PLoS One (2012) 0.76
Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation. Oncotarget (2017) 0.75
Epigenetic reduction of DNA repair in progression to gastrointestinal cancer. World J Gastrointest Oncol (2015) 0.75
Nucleosome Positioning and NDR Structure at RNA Polymerase III Promoters. Sci Rep (2017) 0.75
Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet (2007) 32.41
The epigenomics of cancer. Cell (2007) 30.91
A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A (1992) 29.51
The role of chromatin during transcription. Cell (2007) 26.48
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Genome-scale identification of nucleosome positions in S. cerevisiae. Science (2005) 15.04
Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci (2006) 13.32
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem (1996) 10.86
Cellular differentiation, cytidine analogs and DNA methylation. Cell (1980) 10.15
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Evidence for nucleosome depletion at active regulatory regions genome-wide. Nat Genet (2004) 9.10
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res (1997) 8.88
Genome-scale profiling of histone H3.3 replacement patterns. Nat Genet (2005) 7.22
An abundance of bidirectional promoters in the human genome. Genome Res (2004) 5.90
RNA meets chromatin. Genes Dev (2005) 5.66
Global nucleosome occupancy in yeast. Genome Biol (2004) 5.49
High-throughput mapping of the chromatin structure of human promoters. Nat Biotechnol (2007) 5.24
Histone replacement marks the boundaries of cis-regulatory domains. Science (2007) 4.06
Alternative chromatin structure at CpG islands. Cell (1990) 3.93
Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr Opin Cell Biol (2001) 3.86
Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res (2006) 3.59
Bidirectional gene organization: a common architectural feature of the human genome. Cell (2002) 3.47
The CpG island searcher: a new WWW resource. In Silico Biol (2003) 3.42
Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res (2002) 3.02
Genome-wide identification of DNaseI hypersensitive sites using active chromatin sequence libraries. Proc Natl Acad Sci U S A (2004) 2.94
Removal of promoter nucleosomes by disassembly rather than sliding in vivo. Mol Cell (2004) 2.90
Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res (2002) 2.84
DNA methylation directs a time-dependent repression of transcription initiation. Curr Biol (1997) 2.83
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell (2003) 2.38
Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res (2001) 2.27
Chromatin differences between active and inactive X chromosomes revealed by genomic footprinting of permeabilized cells using DNase I and ligation-mediated PCR. Genes Dev (1991) 2.20
Parental imprinting: potentially active chromatin of the repressed maternal allele of the mouse insulin-like growth factor II (Igf2) gene. Genes Dev (1992) 2.19
Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res (2005) 1.94
Control of transcription through intragenic patterns of nucleosome composition. Cell (2005) 1.77
Coincident start sites for divergent transcripts at a randomly selected CpG-rich island of mouse. EMBO J (1987) 1.68
Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol (1999) 1.49
Constitutive nucleosome depletion and ordered factor assembly at the GRP78 promoter revealed by single molecule footprinting. PLoS Genet (2006) 1.48
Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res (2006) 1.46
Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol Cell Biol (2005) 1.45
DNA methylation, nucleosome formation and positioning. Brief Funct Genomic Proteomic (2005) 1.34
Origins of bidirectional promoters: computational analyses of intergenic distance in the human genome. Mol Biol Evol (2003) 1.20
A determining influence for CpG dinucleotides on nucleosome positioning in vitro. Nucleic Acids Res (2004) 1.19
Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability. Oncogene (2002) 1.12
Hemimethylation and hypersensitivity are early events in transcriptional reactivation of human inactive X-linked genes in a hamster x human somatic cell hybrid. Mol Cell Biol (1992) 1.12
Chromatin structure mapping in vivo using methyltransferases. Methods Enzymol (1996) 1.08
Aberrant silencing of the CpG island-containing human O6-methylguanine DNA methyltransferase gene is associated with the loss of nucleosome-like positioning. Mol Cell Biol (1997) 0.99
Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene (2003) 0.99
Mismatch repair deficiency and CpG island hypermethylation in sporadic colon adenocarcinomas. Cancer Epidemiol Biomarkers Prev (2001) 0.92
Nuclease-hypersensitive chromatin formed by a CpG island in human DNA cloned as an artificial chromosome in yeast. J Biol Chem (2000) 0.80
Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A (2002) 12.33
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
Epigenetics in cancer. Carcinogenesis (2009) 7.49
Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov (2006) 6.39
Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med (2008) 4.41
Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci U S A (2004) 4.39
Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A (2008) 4.20
Rethinking how DNA methylation patterns are maintained. Nat Rev Genet (2009) 4.03
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood (2002) 3.89
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol (2002) 3.61
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
The CpG island searcher: a new WWW resource. In Silico Biol (2003) 3.42
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
DNA methylation and breast carcinogenesis. Oncogene (2002) 3.03
Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res (2002) 3.02
DNA methylation: the nuts and bolts of repression. J Cell Physiol (2007) 3.00
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res (2009) 2.83
Epigenetics and microRNAs. Pediatr Res (2007) 2.52
DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell (2012) 2.45
Preferential response of cancer cells to zebularine. Cancer Cell (2004) 2.39
Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. Mol Cell Biol (2009) 2.34
Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology (2011) 2.33
Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol Cell Biol (2006) 2.28
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet (2010) 2.27
Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci U S A (2006) 2.25
Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst (2003) 2.22
Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues. Nat Genet (2012) 2.20
Polycomb-repressed genes have permissive enhancers that initiate reprogramming. Cell (2011) 2.14
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood (2011) 2.08
Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) (2008) 2.04
Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle (2006) 1.98
Epigenetic changes in cancer. APMIS (2007) 1.96
Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res (2012) 1.95
Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res (2005) 1.94
H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes. Mol Cell (2010) 1.85
Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol Cancer Ther (2005) 1.85
DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet (2011) 1.83
DNA methylation and cellular reprogramming. Trends Cell Biol (2010) 1.77
Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun (2008) 1.74
Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res (2002) 1.71
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res (2004) 1.69
Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res (2004) 1.68
Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol (2004) 1.68
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res (2007) 1.65
Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J Cancer (2009) 1.64
Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res (2003) 1.62
Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci (2010) 1.61
Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene (2002) 1.59
Preoperative sentinel node identification with ultrasound using microbubbles in patients with breast cancer. AJR Am J Roentgenol (2011) 1.58
Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet (2011) 1.56
The nuclear-envelope protein and transcriptional repressor LAP2beta interacts with HDAC3 at the nuclear periphery, and induces histone H4 deacetylation. J Cell Sci (2005) 1.54
High-grade lung adenocarcinoma with fetal lung-like morphology: clinicopathologic, immunohistochemical, and molecular analyses of 17 cases. Am J Surg Pathol (2013) 1.53
OCT4 establishes and maintains nucleosome-depleted regions that provide additional layers of epigenetic regulation of its target genes. Proc Natl Acad Sci U S A (2011) 1.51
Constitutive nucleosome depletion and ordered factor assembly at the GRP78 promoter revealed by single molecule footprinting. PLoS Genet (2006) 1.48